---
title: "Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3… — report author — DecisionGateway"
description: "prediction by report author, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965"
meta:
  "og:description": "prediction by report author, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3… — report author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

prediction

# **Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3 registrational trials are expected in 2027.**

A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *2027년 그레이브스병(GD) 2b상 및 중증근무력증(MG) 3상 등 허가 목적 임상 탑라인 데이터 발표 기대*

companyreportPublished 2026-11-10 [ Read source](https://t.me/companyreport/116013)

## **Discussion**

## **Related claims**

[**From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and MG (Phase 3) top-line results are scheduled for 2027.**하나증권 제약/바이오 김선아 · commitment](https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492) [**Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027.**하나증권 제약/바이오 김선아 · commitment](https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea) [**В 2027 году станут доступны препараты для лечения меланомы кожи и опухолей желудочно-кишечного тракта для граждан в рамках ОМС.**Голикова · prediction](https://dgw.tmarket.io/claims/01a1bffc-9364-7854-95bc-e231f600dfe8) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6d1-7aec-8105-c4689a803513) [**在2026年10月13日或之后提交的申请将不会被受理，直至另行通知。**汇丰香港 · prediction](https://dgw.tmarket.io/claims/01a1d5e3-8e58-7445-9047-23ac0007964b) [**Moody's Ratings said in its outlook report that credit conditions are expected to deteriorate in 2027, with high financing costs and pressure from energy prices weighing on highly leveraged companies and interest-rate-sensitive sectors.**穆迪评级 · prediction](https://dgw.tmarket.io/claims/01a1cbdc-3ab4-75a1-83a4-358e5be2ce01)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965#webpage","@type":"WebPage","description":"prediction by report author, recorded recently — verbatim quote and source citation.","name":"Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3… — report author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Topline data from the Graves' disease (GD) Phase 2b and…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/companyreport/116013","text":"2027년 그레이브스병(GD) 2b상 및 중증근무력증(MG) 3상 등 허가 목적 임상 탑라인 데이터 발표 기대","url":"/claims/01a1d4b6-f70a-7976-b000-2e65792a1965"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.